AbsorbThis Blog

Home>>AbsorbThis Blog

Why Cell & Gene Therapy Focuses on the Eye

Many companies are developing cell and gene therapy for ocular diseases. There are more than 25 companies developing cell and gene therapy (CGT) for ocular diseases with more [...]

Gut Reactions: An ADME-Centric View of the Gut Microbiome

Did you know that, although we’re 100% human at birth, by adulthood we’re 90% bacteria?  That’s because we harbor ten times more bacterial cells in our microbiome [...]

2019-09-12T15:15:32-04:00September 9, 2019|Categories: AbsorbThis Blog|Tags: , |

Key Takeaways from The Bioprocessing Summit: Gene Therapy CMC and Analytics

Last week, at The Bioprocessing Summit in Boston’s Seaport district, we heard from industry leaders on their CMC and analytical strategies for developing gene therapy products. This was [...]

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation

Perspectives From the International Transporter Consortium Introduction Transporter studies are performed at various stages of drug development ‒ discovery to first-in-human (FIH) phase (in-vitro substrate and inhibition [...]

2019-08-20T12:39:25-04:00August 20, 2019|Categories: AbsorbThis Blog, Drug Transporters|

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition

Introduction P-glycoprotein (P-gp) is a drug transporter recommended by regulatory agencies for in-vitro and in-vivo DDI evaluation. Due to high inter-laboratory variability in in-vitro P-gp data, regulators [...]

2019-07-18T15:00:45-04:00July 18, 2019|Categories: AbsorbThis Blog, Drug Transporters|Tags: , , |